دورية أكاديمية
Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status
| العنوان: | Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status |
|---|---|
| المؤلفون: | Alafandi, A., van Garderen, K. A., Klein, S., van der Voort, S. R., Rizopoulos, D., Nabors, L., Stupp, R., Weller, M., Gorlia, T., Tonn, J. C., Smits, M. |
| المصدر: | Alafandi , A , van Garderen , K A , Klein , S , van der Voort , S R , Rizopoulos , D , Nabors , L , Stupp , R , Weller , M , Gorlia , T , Tonn , J C & Smits , M 2023 , ' Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status ' , European Journal of Cancer , vol. 188 , pp. 122-130 . https://doi.org/10.1016/j.ejca.2023.04.021Test |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being |
| الوصف: | Purpose: We retrospectively evaluated the association between postoperative pre-radiotherapy tumour burden and overall survival (OS) adjusted for the prognostic value of O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with newly diagnosed glioblastoma treated with radio-/chemotherapy with temozolomide. Materials and methods: Patients were included from the CENTRIC (EORTC 26071-22072) and CORE trials if postoperative magnetic resonance imaging scans were available within a timeframe of up to 4 weeks before radiotherapy, including both pre- and post-contrast T1w images and at least one T2w sequence (T2w or T2w-FLAIR). Postoperative (residual) pre-radiotherapy contrast-enhanced tumour (CET) volumes and non-enhanced T2w abnormalities (NT2A) tissue volumes were obtained by three-dimensional segmentation. Cox proportional hazard models and Kaplan Meier estimates were used to assess the association of pre-radiotherapy CET/NT2A volume with OS adjusted for known prognostic factors (age, performance status, MGMT status). Results: 408 tumour (of which 270 MGMT methylated) segmentations were included. Median OS in patients with MGMT methylated tumours was 117 weeks versus 61 weeks in MGMT unmethylated tumours (p < 0.001). When stratified for MGMT methylation status, higher CET volume (HR 1.020; 95% confidence interval CI [1.013–1.027]; p < 0.001) and older age (HR 1.664; 95% CI [1.214–2.281]; p = 0.002) were significantly associated with shorter OS while NT2A volume and performance status were not. Conclusion: Pre-radiotherapy CET volume was strongly associated with OS in patients receiving radio-/chemotherapy for newly diagnosed glioblastoma stratified by MGMT promoter methylation status. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://pure.eur.nl/en/publications/2a2410f9-52d6-42cc-bec1-12aefff5a491Test |
| DOI: | 10.1016/j.ejca.2023.04.021 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2023.04.021Test https://pure.eur.nl/en/publications/2a2410f9-52d6-42cc-bec1-12aefff5a491Test https://pure.eur.nl/ws/files/93235059/s12889_023_15746_0.pdfTest http://www.scopus.com/inward/record.url?scp=85159809153&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.683BEA60 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ejca.2023.04.021 |
|---|